Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Europe Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Europe Castrate-resistant Prostate Cancer Market by Therapy
4.1 Europe Hormonal Therapy Market by Country
4.2 Europe Immunotherapy Market by Country
4.3 Europe Chemotherapy Market by Country
4.4 Europe Radiotherapy Market by Country
Chapter 5. Europe Castrate-resistant Prostate Cancer Market by Country
5.1 Germany Castrate-resistant Prostate Cancer Market
5.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2 UK Castrate-resistant Prostate Cancer Market
5.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.3 France Castrate-resistant Prostate Cancer Market
5.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.4 Russia Castrate-resistant Prostate Cancer Market
5.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.5 Spain Castrate-resistant Prostate Cancer Market
5.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.6 Italy Castrate-resistant Prostate Cancer Market
5.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
Unique Offerings 
